FOLR1 expression

Complete resection and advanced stage were suggested as prognostic factors in UCS. FRα and Trop-2 are increasingly recognized as therapeutic targets and their elevated expression levels in the epithelial component of UCS are promising, although not associated with prognosis in this cohort.

Decellularized LNs had comparable collagen and GAG concentrations to native tissue, and immunofluorescence staining showed the presence of other ECM proteins. Decellularized sections sustained 21-day FRC culture, enabled FRC-T cell co-culture, and supported high-resolution imaging and flow cytometric analyses, revealing altered gp38 and PDGFRα expression in FRCs relative to 2D culture.

Our results demonstrate that active targeting of chemotherapy-loaded NPs with a FRα ligand, pemetrexed, enhances tumor targeting and antitumor efficacy in a CRC model.

MIRV demonstrates significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer. Its use in platinum-resistant ovarian cancer with high FRα expression represents a particularly promising Therapeutic approach. Furthermore, the combination of MIRV and bevacizumab shows substantial potential for improving outcomes in patients with platinum-resistant disease.

HER2 overexpression is relatively common and had prognostically relevant in BRCA1/2-mutated/HRD and in mucinous or clear cell OC. Further clinical trials are warranted to optimize use of HER2- and FRα-targeted ADCs in these group.

AZD5335 is a promising next-generation ADC capable of targeting ovarian cancers with both high and low FRα expression. AZD5335 demonstrates efficacy in overcoming Elahere-resistance and supports combined treatment strategies.

P3, N=520, Recruiting, AbbVie | Trial primary completion date: Apr 2029 --> Mar 2027

P2/3, N=600, Terminated, Sutro Biopharma, Inc. | Trial completion date: Feb 2028 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Aug 2025; Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta

These molecular, cellular, and functional phenotypes are associated with neonatal and long-term motor impairments. Our findings highlight the contribution of the endothelial NMDA receptor on the differentiation of oligodendrocytes entering the sensorimotor cortex along microvessels.

Real-world experience with mirvetuximab demonstrated a favorable safety profile and clinical benefit in platinum-resistant ovarian cancer. Taxane therapy immediately preceding mirvetuximab was associated with shorter overall survival but not increased neurotoxicity.

These results demonstrate a potential therapeutic option for patients with advanced OS. FH FOLR1 CART is advancing to an early phase trial in relapsed/refractory OS at Fred Hutch Cancer Center and Seattle Children's Hospital.

P2, N=125, Active, not recruiting, AbbVie | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026